Retinoid Radiotherapy Combination Overcomes Immune Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments like chemotherapy and radiotherapy are limited by side effects and the development of drug- and radio-resistant cancer cells, necessitating the need for enhanced anticancer methods that can effectively target solid tumors without promoting resistance.

Innovation Solution

Combining the administration of a retinoid, such as all-trans retinoic acid (ATRA), with ionizing irradiation and immunotherapy, specifically using checkpoint blockade, to enhance tumor growth control and induce antitumor immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high dosage chemotherapy or radiotherapy is used to treat cancer, then tumor growth control is improved, but side effects to healthy cells and development of resistance worsen

Engineering Contradiction:

Improvetumor growth controlVSAvoidside effects to healthy cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the treatment by introducing retinoids (vitamin A derivatives) that modify the biochemical environment of tumor cells. This allows for altered cellular responses to radiation and chemotherapy, enabling effective treatment at lower doses that reduce damage to healthy cells while maintaining or improving tumor control through enhanced differentiation and sensitization mechanisms

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite therapeutic approach by combining retinoids with conventional radiotherapy and chemotherapy. This multi-component treatment strategy creates synergistic effects where retinoids enhance the efficacy of radiation and chemotherapeutic agents while reducing their toxic side effects, allowing for improved tumor control with lower individual dosages of each agent

Inventive Principle:

Principle #40Composite materials

2Reliability

If high dosage chemotherapy or radiotherapy is used to treat cancer, then tumor growth control is improved, but development of drug- and radio-resistance worsens

Engineering Contradiction:

Improvetumor growth controlVSAvoiddrug- and radio-resistance

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies retinoids as a preliminary action before or during radiotherapy and chemotherapy treatment. This pre-treatment with retinoids sensitizes tumor cells to the subsequent therapeutic agents, preventing the development of resistance by interfering with the adaptive survival mechanisms that tumor cells would otherwise activate in response to high-dose treatment stress

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent modifies the biochemical parameters of tumor cells through retinoid administration, altering gene expression profiles and cellular differentiation states. These parameter changes prevent tumor cells from developing resistant phenotypes by redirecting them toward differentiated states that are more susceptible to conventional therapies and less capable of mounting resistance responses

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If fractionated, low dose radiotherapy is used to reduce side effects, then harm to healthy cells is reduced, but tumor treatment effectiveness worsens

Engineering Contradiction:

Improveside effects to healthy cellsVSAvoidtumor treatment effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent introduces retinoids as an intermediary substance that mediates between fractionated low-dose radiotherapy and tumor control. The retinoids act as chemical mediators that amplify the anti-tumor effects of low-dose radiation while protecting healthy tissues, enabling the use of gentler radiation protocols without sacrificing therapeutic efficacy through enhanced biological sensitivity induction

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This combination provides enhanced tumor growth control, increases inducible nitric oxide synthase (iNOS)-producing myeloid cells, and promotes adaptive immunity, leading to improved treatment outcomes for solid tumors, including those resistant to conventional therapies, with potential for lower radiation doses and reduced recurrence.

Implementation Method 1

exposing at least a portion of the subject to ionizing irradiation energy

Methodology Applied

Scientific EffectIonizing radiation: Radiation

Data Source

PatentUS20240000741A1All-trans retinoic acid enhances radiotherapy and overcomes immune suppression for cancer therapy

Publication Date: 2024.01.04 UNIVERSITY OF CHICAGO

AI summary

Methods of treating cancer comprising the use of combinations of a retinoid, e.g., all-trans retinoic acid (ATRA), and radiotherapy are described. The administration of a retinoid can enhance the effect of radiotherapy, including enhancing fractionated, low-dose radiotherapy. Use of the combination increases tumor necrosis factor alpha (TNF-α)- and inducible nitric oxide synthase (iNOS)-producing inflammatory macrophages in local (radiated) and distal (non-radiated) tumors. The methods can optionally further involve the use of checkpoint blockade immunotherapy.